Don't have to be a genius to see that this will have some level of pullback. Although, specifically, I'll target 7 and add to my short if it goes over 12.
On August 27, Lannett Company reported its fourth-quarter earnings results. The company reported revenues of $133.84 million, a year-over-year decline of 21.69%. However, this was $13.56 million higher than the consensus estimate. The company also reported non-GAAP EPS (earnings per share) of $0.37. This is $0.16 higher than the consensus.
Lannett Company has...
With an intraday move of currently 42.81%, and intraday high of $8.95 and a short float percentage of 74.27% LCI looks like an interesting short-squeeze opportunity. The RSI indicated several overbought conditions with a cross at the 69.95 level, that followed a sharp sell-off. If you are interested in finding optimal RSI levels for individual stocks, please check...
This isn't just any double bottom. This is a double bottom in a penny stock with awesome analyst ratings and some of the biggest short squeeze potential in the market right now. When this runs, it could run fast.
Potential Long setup on LCI; awaiting price confirmation at a higher level - high risk trade profile contingent on upcoming earnings. Hope to see price break higher on positive earnings report.
Trade responsibly; TPs and SLs
In weekly TF looked cooked enough and below lows, MACD building trend up while the price itself stay the same.
in 4H same thing .
Balance sheet seem decent enough and with some luck well get some positive news about the pipeline .
first destination around 17$ and with a lot of luck maybe well get 20 +
good luck
not a recomandation to do anything in the stock...
Good company with positive chart indicators that had 41% short interest on 2/28.. big gap up at $19.75. Holding $16.35 and will sell if falls below $15 and take aanother look if and when it hits $18.35 (~12%)
LCI going up forming a bump & run or falling angel type of pattern. Moneyflow is accumulating & turning to positive side. We think it will continue up trend for a while.
Investors seems very bullish on this as Calls outnumbered puts by a bullish 31-to-1 ratio.
So we would consider $25 November Calls currently $1.30 or $25 December Calls currently $1.90
You...
LCI is currently trading near a downtrend resistance line with earnings next tuesday. 9 out of the last ten earnings reports have seen positive moves upward or at least traded flat a week or two after the release. Increasing fundamental indicators as well as a recent approval for a generic drug, a month ago, in July contributed to the recent reversal of the...
Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
LCI
